• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

    12/27/23 8:14:19 AM ET
    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Steel/Iron Ore
    Industrials
    EDP Services
    Technology
    Get the next $ACNT alert in real time by email

    Shares of Ascent Industries Co. (NASDAQ:ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal.

    Ascent Industries shares surged 7.4% to $8.69 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Jet.AI Inc. (NASDAQ:JTAI) shares gained 71.1% to $2.74 in pre-market trading after falling 39% on Tuesday.
    • Bit Brother Limited(NASDAQ:BETS) gained 40.4% to $0.0155 in pre-market trading after jumping 111% on Tuesday.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) rose 38.8% to $0.88 in pre-market trading.
    • Coherus BioSciences, Inc. (NASDAQ:CHRS) shares rose 34.8% to $2.94 in pre-market trading after the company reported the FDA approval of UDENYCA ONBODY for pegfilgrastim-cbqv.
    • Dunxin Financial Holdings Limited (NYSE:DXF) shares gained 25.2% to $0.41 in pre-market trading after gaining 9% on Tuesday.
    • RiskOn International, Inc. (NASDAQ:ROI) gained 20.3% to $0.1701 in pre-market trading after declining 11% on Tuesday
    • Mobile Global Esports Inc. (NASDAQ:MGAM) shares rose 19.5% to $0.46 in pre-market trading after gaining 33% on Tuesday.
    • Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares climbed 14.2% to $1.60 in pre-market trading. Reneo Pharmaceuticals, said on Dec 26, Concentra, an affiliate of Tang Capital Partners, sent an acquisition proposal to the company
    • Atreca, Inc. (NASDAQ:BCEL) gained 8.6% to $0.1847 in pre-market trading. Atreca shares fell over 22% on Tuesday after the company announced the sale of a collection of antibody-related assets and materials to Immunome consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.

    Losers

    • Nukkleus Inc. (NASDAQ:NUKK) shares fell 17.8% to $3.00 in pre-market trading after jumping around 11% on Tuesday.
    • Mobix Labs, Inc. (NASDAQ:MOBX) shares fell 14.6% to $5.98 in pre-market trading after surging over 34% on Tuesday.
    • Oncternal Therapeutics, Inc. (NASDAQ:ONCT) shares fell 12% to $0.52 in pre-market trading. Oncternal Therapeutics updated the status of a recent study involving a treatment for relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR-T treatment.
    • Smart for Life, Inc. (NASDAQ:SMFL) shares fell 11.5% to $1.62 in pre-market trading after declining 7% on Tuesday.
    • Kelso Technologies Inc. (NASDAQ:KIQ) shares fell 10.1% to $0.15 in pre-market trading after gaining around 15% on Tuesday.
    • PaxMedica, Inc. (NASDAQ:PXMD) fell 10% to $0.8009 in pre-market after jumping 10% on Tuesday.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares fell 8.7% to $0.21 in pre-market trading. Brainstorm Cell Therapeutics shares gained 16% on Tuesday after the company announced that it was granted patents for Allogeneic Exosome Platform-Product in neurological disorder treatments.
    • ARB IOT Group Limited (NASDAQ:ARBB) fell 8.4% to $2.37 in pre-market trading after surging 175% on Tuesday.
    • Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) shares fell 7.8% to $1.17 in pre-market trading. Inspira Technologies shares gained 5% on Tuesday after the company announced 95% accuracy results for HYLA Blood Sensor. Additionally, the company plans FDA submission for clearance in 2024.
    • FLJ Group Limited (NASDAQ:FLJ) fell 7.2% to $1.16 in pre-market trading after gaining 5% on Tuesday.

     

    Now Read This: Beat Inflation With These 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street's Most Accurate Analysts

    Get the next $ACNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACNT
    $ARBB
    $BCEL
    $BCLI

    CompanyDatePrice TargetRatingAnalyst
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Coherus Oncology Inc.
    $CHRS
    9/4/2025Hold → Buy
    Maxim Group
    Coherus Oncology Inc.
    $CHRS
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    Reneo Pharmaceuticals Inc.
    $RPHM
    12/15/2023Outperform → Market Perform
    Leerink Partners
    Reneo Pharmaceuticals Inc.
    $RPHM
    12/15/2023Buy → Hold
    Jefferies
    Reneo Pharmaceuticals Inc.
    $RPHM
    12/15/2023$30.00 → $1.50Buy → Neutral
    H.C. Wainwright
    Reneo Pharmaceuticals Inc.
    $RPHM
    12/14/2023Buy → Neutral
    Ladenburg Thalmann
    Reneo Pharmaceuticals Inc.
    $RPHM
    12/14/2023$23.00 → $1.45Buy → Underperform
    BofA Securities
    More analyst ratings

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    SEC Filings

    View All

    SEC Form 10-K filed by Coherus Oncology Inc.

    10-K - Coherus Oncology, Inc. (0001512762) (Filer)

    3/9/26 4:56:30 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Coherus Oncology, Inc. (0001512762) (Filer)

    3/9/26 4:40:39 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Jet.AI Inc.

    10-K - Jet.AI Inc. (0001861622) (Filer)

    3/6/26 4:47:18 PM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus BioSciences upgraded by Maxim Group

    Maxim Group upgraded Coherus BioSciences from Hold to Buy

    9/4/25 7:57:13 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus BioSciences downgraded by UBS with a new price target

    UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously

    8/16/24 7:33:26 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Sales & Bus. Development Pan Anthony X bought $45,234 worth of shares (3,400 units at $13.30), increasing direct ownership by 20% to 20,651 units (SEC Form 4)

    4 - ASCENT INDUSTRIES CO. (0000095953) (Issuer)

    3/9/26 10:39:57 AM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    Chief Executive Officer Kitchen John Bryan covered exercise/tax liability with 1,220 shares, decreasing direct ownership by 2% to 72,390 units (SEC Form 4)

    4 - ASCENT INDUSTRIES CO. (0000095953) (Issuer)

    2/12/26 5:16:03 PM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    Chief Financial Officer Kavalauskas Ryan covered exercise/tax liability with 867 shares, decreasing direct ownership by 6% to 14,428 units (SEC Form 4)

    4 - ASCENT INDUSTRIES CO. (0000095953) (Issuer)

    2/12/26 3:54:46 PM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

    – LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. "We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars

    3/9/26 4:15:00 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jet.AI Inc. Reports Full Year 2025 Financial Results

    LAS VEGAS, March 09, 2026 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (NASDAQ:JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, today announced financial results for the full year ended December 31, 2025. The Company had approximately $13.7 million of cash and no debt as of March 5th, 2026 (vs $1.8 million at year end 2025) and is Net Income positive for the full year 2025 ($4.6 million in 2025 vs -$12.7 million in 2024). In the first quarter of 2026, Jet.AI expects the completion of the third milestone of its Canadian data center joint venture - related to powered land at its 385 acre Manitoba site and continued progress in the Marit

    3/9/26 8:30:00 AM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    Strategic Investor Agrees to $80 Million Investment in the Company at $2.00 Per Share, Preliminary Participation in Management, Followed by Subsequent Crypto Contribution

    HANGZHOU, China, March 06, 2026 (GLOBE NEWSWIRE) -- Jiuzi Holdings, Inc. (NASDAQ:JZXN, the ", Company", or ", Jiuzi", )), today announced that it has reached an agreement and executed an investment agreement with a strategic investment institution possessing globally leading influence in the fields of crypto asset investment and Crypto treasury management. Pursuant to the agreement, the strategic investor will initially subscribe for 40 million ordinary shares of the Company at a price of $2.00 per share, representing a total investment amount of $80 million, to be funded in cash. This initial investment was completed and closed today, whereby the strategic investor has preliminarily comm

    3/6/26 7:15:00 AM ET
    $JZXN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Sales & Bus. Development Pan Anthony X bought $45,234 worth of shares (3,400 units at $13.30), increasing direct ownership by 20% to 20,651 units (SEC Form 4)

    4 - ASCENT INDUSTRIES CO. (0000095953) (Issuer)

    3/9/26 10:39:57 AM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    VP, Operations - Chemicals Srinivas Ravi Ramesh bought $49,760 worth of shares (4,000 units at $12.44), increasing direct ownership by 33% to 16,000 units (SEC Form 4)

    4 - ASCENT INDUSTRIES CO. (0000095953) (Issuer)

    6/18/25 4:22:30 PM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    VP, Sales & Bus. Development Pan Anthony X bought $62,990 worth of shares (5,400 units at $11.66), increasing direct ownership by 38% to 14,570 units (SEC Form 4)

    4 - ASCENT INDUSTRIES CO. (0000095953) (Issuer)

    5/16/25 3:00:58 PM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

    – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

    11/6/25 1:54:45 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 3:40:00 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Financials

    Live finance-specific insights

    View All

    Ascent Industries Co. Announces Fourth Quarter and Full Year 2025 Results

    Ascent Industries Co. (NASDAQ:ACNT) ("Ascent" or the "Company"), a specialty chemicals platform delivering differentiated, performance-driven chemical solutions, is reporting its results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Summary1 (in millions, except per share and margin) Q4 2025 Q4 2024 Change Net Sales $18.8 $18.1 3.9% Gross Profit $3.4 $3.5 (2.9)% Gross Profit Margin 18.3% 19.2% -90bps Net Income (Loss) $(1.0) $0.2 (600.0)% Diluted Income (Loss) per Share $(0.11) $0.01 (1200.0)% Adjuste

    3/3/26 4:05:00 PM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ascent Industries Sets Fourth Quarter 2025 Earnings Conference Call for March 3, 2026, at 5:00 p.m. ET

    Ascent Industries Co. (NASDAQ:ACNT) ("Ascent" or the "Company"), a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions, will hold a conference call on Tuesday, March 3, 2026, at 5:00 p.m. Eastern time to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The results will be reported in a press release prior to the conference call. Ascent management will host the conference call, followed by a question-and-answer period. Date: Tuesday, March 3, 2026 Time: 5:00 p.m. Eastern time Webcast Registration Link: Here Dial-in Link: Here To access the call by phone, plea

    2/17/26 8:00:00 AM ET
    $ACNT
    Steel/Iron Ore
    Industrials

    $ACNT
    $ARBB
    $BCEL
    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Smart for Life Inc.

    SC 13G/A - SMART FOR LIFE, INC. (0001851860) (Subject)

    11/14/24 6:49:12 PM ET
    $SMFL
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care